Session » Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment III: AxSpA
- 4:00PM-5:30PM
-
Abstract Number: 2546
Anti-infliximab Antibodies as a Marker of Drug Survival and Tapering in Ankylosing Spondylitis Patients: 12 Years Follow-up
- 4:00PM-5:30PM
-
Abstract Number: 2547
Characteristics of Difficult-To-Treat Axial Spondyloarthritis: Results of a Multicentric Retrospective Study
- 4:00PM-5:30PM
-
Abstract Number: 2549
Effect of Ixekizumab Treatment on MRI Structural Lesions in the Sacroiliac Joints of Patients with Radiographic Axial Spondyloarthritis; A Post-hoc Analysis of a Placebo and Active Controlled RCT
- 4:00PM-5:30PM
-
Abstract Number: 2545
Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Axial Spondyloarthritis: Results from a Randomized, Double-Blind, Phase 3 Study
- 4:00PM-5:30PM
-
Abstract Number: 2548
Low Uveitis Rates in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Pooled Results from Phase 2b/3 Trials